Skip to content

Study · Randomized controlled trial · n = 19 · 1996

5 results

A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.

Andreone P, Cursaro C, Gramenzi A, Buzzi A, Covarelli MG, Di Giammarino L, Miniero R, Arienti V, Bernardi M, Gasbarrini G

Liver1 Jun 1996Cited by 25 (Europe PMC)

PMID8873009 (opens in a new tab)DOI10.1111/j.1600-0676.1996.tb00729.x (opens in a new tab)PepBankPUB-08873009
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis C, one patient on thymosin alpha‑1 and none on placebo normalized serum ALT by the end of treatment, and that patient relapsed at the sixth month of follow-up.

    In plain wordsIn people with chronic hepatitis C, one patient on thymosin alpha‑1 and none on placebo had normal liver enzymes at treatment end, then relapsed.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeNormalization of serum ALT by end of treatment
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    900 micrograms/m2 twice weekly · six monthsAs given in this study (human).

    Source sentences

    Summary
    One patient treated with thymosin alpha 1, but no patient in the placebo group, normalized serum ALT levels by the end of the treatment. This patient, however, relapsed at the sixth month of the follow up.
    1 context sentence
    Summary · context
    Nineteen Italian patients with chronic active hepatitis C, proven by biopsy were randomly assigned to receive a six month course of thymosin alpha 1 (900 micrograms/m2 of body surface area twice weekly) or a placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis C, mean serum ALT levels did not change significantly in either the thymosin alpha‑1 or the placebo group during treatment or follow-up.

    In plain wordsIn people with chronic hepatitis C, liver enzyme (ALT) levels did not change significantly with thymosin alpha‑1 or with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeMean serum ALT during treatment and follow-up
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    900 micrograms/m2 twice weekly · six monthsAs given in this study (human).

    Source sentences

    Summary
    Overall, there were no significant changes in mean serum ALT levels in either group during the treatment or follow-up period.
    1 context sentence
    Summary · context
    Nineteen Italian patients with chronic active hepatitis C, proven by biopsy were randomly assigned to receive a six month course of thymosin alpha 1 (900 micrograms/m2 of body surface area twice weekly) or a placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In chronic hepatitis C, no patient cleared HCV-RNA.

    In plain wordsIn people with chronic hepatitis C, no one given thymosin alpha‑1 or placebo cleared the hepatitis C virus.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeHCV-RNA clearance
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Antiviral activity · Liver
    Studied dose
    900 micrograms/m2 twice weekly · six monthsAs given in this study (human).

    Source sentences

    Summary
    No patient cleared HCV-RNA.
    1 context sentence
    Summary · context
    Nineteen Italian patients with chronic active hepatitis C, proven by biopsy were randomly assigned to receive a six month course of thymosin alpha 1 (900 micrograms/m2 of body surface area twice weekly) or a placebo.
  4. 04HumanRandomized controlled trialSafety outcome

    In chronic hepatitis C, no side effects were reported with thymosin alpha‑1 except local discomfort at the injection sites, reported by some patients.

    In plain wordsIn people with chronic hepatitis C, thymosin alpha‑1 caused no reported side effects except discomfort at the injection site in some patients.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableLocal discomfort at injection sites
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    900 micrograms/m2 twice weekly · six monthsAs given in this study (human).

    Source sentences

    Summary
    No side effects were reported except for local discomfort at the injection sites, reported by some patients treated with thymosin alpha 1.
    1 context sentence
    Summary · context
    Nineteen Italian patients with chronic active hepatitis C, proven by biopsy were randomly assigned to receive a six month course of thymosin alpha 1 (900 micrograms/m2 of body surface area twice weekly) or a placebo.
  5. 05HumanRandomized controlled trialSafety outcome

    In chronic hepatitis C, all patients completed the trial.

    In plain wordsIn people with chronic hepatitis C, all patients finished the trial.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTrial completion
    Study

    n = 19

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    900 micrograms/m2 twice weekly · six monthsAs given in this study (human).

    Source sentences

    Summary
    All patients completed the trial.
    1 context sentence
    Summary · context
    Nineteen Italian patients with chronic active hepatitis C, proven by biopsy were randomly assigned to receive a six month course of thymosin alpha 1 (900 micrograms/m2 of body surface area twice weekly) or a placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.